Index

Note: Page numbers in italics refer to figures; page numbers in bold refer to tables
Abbreviations used in subentries

AML – acute myeloid leukaemia
AMML – acute myelomonocytic leukaemia
MDS – myelodysplastic syndromes
MGLUS – monoclonal gammopathy of undetermined significance

Abbott Sapphire system
acanthocytes
acquired immune deficiency syndrome (AIDS)
acid phosphatase reaction
acanthocytosis

Abbreviations used in subentries


bone marrow aspirate
bone marrow aspirate cytology
bone marrow aspirate

767
acute myeloid leukaemia with eosinophilia and inv(16) or t(16;16) (cont'd)
immunophenotyping 312
peripheral blood film 305, 309
acute myeloid leukaemia with granulocytic differentiation 295, 297
acute myeloid leukaemia with granulocytic maturation 347–355, 353–357
cytchemistry 347
differential diagnosis 355
hypercellularity 357
immunophenotyping 355
myeloid markers 355
acute myeloid leukaemia with hyperexpression of EVI1 336
acute myeloid leukaemia with inv(3)(q21q26.2) 336
acute myeloid leukaemia with minimal differentiation 344–346
cytchemistry 345
differential diagnosis 346
immunophenotyping 345, 346
peripheral blood 345, 349, 350
acute myeloid leukaemia with mutation of CEBPA (without maturation) 336
acute myeloid leukaemia with myelodysplasia-related changes (AML with MRC) 336–342, 342–348,
413, 414, 415
cytogenetic anomalies 339
de novo 340
dysplastic changes 340, 342–348
dysplastic features, absence of 340
evolution from MDS 340, 347, 348
leucocytosis 414, 435
PANDA classification 414
prognosis 340–342
acute myeloid leukaemia with NPM1 mutation 336, 340, 341
acute myeloid leukaemia without granulocytic maturation 346–347, 349, 351, 352
acute myeloid leukaemia with recurrent genetic abnormalities 300–336
antigen profiles 299
characteristic morphology 300–336
cytograms 406
fusion gene formation 300–336
hyperdeposinophilia 309, 313, 500
other types 328–336
prognosis 300
subgroups 300
acute myeloid leukaemia with t(3;3)(q21q26.2) 336, 337, 338
acute myeloid leukaemia with t(8;21) 300, 301–305, 411
blast cells 302–304, 302–308
bone marrow infiltration 301, 302
cytchemistry 305
cytograms 406, 411
immunophenotyping 305
PANDA classification 411
therapy-related 387, 388, 393
acute myeloid leukaemia with t(9;11) 300
acute myeloid leukaemia with t(6;9)(p23;q43), basophilia and multilineage dysplasia 330, 334, 335, 336
cytchemistry 335
immunophenotyping 330
toluidine blue staining, 335
acute myeloid leukaemia (megakaryoblastic) with t(1;22)(p13;q13) 336, 339
acute myeloid leukaemia (monoblastic) with t(9;11) (p22;q13) 329, 332, 333
cytchemistry 329, 333
immunophenotyping 329
acute myeloid leukaemia with trilineage myelodysplasia see acute myeloid leukaemia with myelodysplasia-related changes (AML with MRC)
acute myeloid leukaemia with variant translocations involving RARA 327–328
acute myeloid leukaemia with variant translocation t(5;17) with NPM1-RARA fusion gene 327–328
acute myeloid leukaemia with variant translocation t(11;17) with ZBTB16-RARA fusion gene 327, 331
acute myelomonocytic leukaemia (AMML) 355–359
bone marrow aspirate 358, 359–363
chronic myelomonocytic leukaemia vs. 325
cytchemistry 296, 297–298, 299, 361
granulocytic differentiation 358–359, 362
immunophenotyping 359
monocytic differentiation 363
therapy-related 395
acute myelomonocytic leukaemia with eosinophilia and inv(16) 305, 310, 311
proeosinophilic granules 312, 312, 313
bone marrow aspirate 384, 387
bone marrow biopsy 384
clinical manifestation 384
differential diagnosis 387
acute promyelocytic leukaemia (APL) 312–328
antigenic profile 323
atypical morphology 324
classic form 314
microgranular variant 325–327
cytchemistry 297, 319, 322
cytogenetic and molecular analysis 327
cytograms 406, 412, 413
hypergranular see hypergranular promyelocytic leukaemia
immunophenotyping 322–323
intermediate forms 327, 329, 330
microgranular variant 323–327, 326, 327, 328
acute monoblastic leukaemia vs. 363–365
bone marrow aspirate 325
cytchemistry 297
immunophenotyping 327
leucocytosis 323, 326, 413
leukaemic cell nuclear configuration 325, 326, 327, 328
peripheral blood film 325–326, 325
report 413
morphology 296
pancytopenia at presentation 412
(t15;17)(q22;q12) genetic alteration 314
therapy 314, 323, 325
acute undifferentiated leukaemia (AUL) 580
denosarkoma, metastes 753
adipocytes (adipose cells) 78, 84
adipose cells (adipocytes) 78, 84
adult T-cell leukaemia/lymphoma (ATLL) 656,
659–664
disease forms 661
genetic analysis 664
immunophenotype 664
morphology 661–664, 663, 664
symptoms 663
ultrastructural examination 662–664
adventitial reticular cells 76–78, 83, 84
nucleus 84
syncytium 84
ADVIA 120 system see ADVIA systems
ADVIA 2120 system see ADVIA systems
ADVIA systems 93, 168
AML 405
basophil/nuclear density channel 404–405, 405
nuclear density analysis 406
blast cells 405, 405, 406
cytogram 141, 141
erthrocyte fragments counts 142–143
histograms 141, 141–142
HPX (high peroxidase) percentage 404
hypochromic erythrocyte measurement 141, 141–142
large unstained cells (LUC) percentage 404
leukaemic cells 404–405
lobularity index (LI) 405
mononuclear cells (MN) 405
MPX (median peroxidase index) 404
neutrophil left shift flag 405
PANDA classification 408–409
AML NOS with maturation 406, 415
matrix table 410
neoplastic disorders 405–406, 407
peroxidase channel 404, 405, 405, 406, 407,
408–409
polymerophonclears (PMN) 405, 405
refractory anaemia with ring sideroblasts 260
reticulocyte count 143
aggressive NK cell leukaemia 655, 656, 659, 662
immunophenotyping 659
aggressive systemic mastocytosis 478, 481
agranular blast cells 214
AML 289, 290
AML with minimal differentiation 345
AML with myelodysplasia-related changes 344
AMML 358
AMML with eosinophilia and inv(16) 311
MDS 231, 234, 235, 237
morphology 214, 289
primary myelofibrosis 479
refractory anaemia with excess of blasts type 2 265
therapy-related AML 396
agranular myeloblast 50
AIDS 727
Burkitt lymphoma 652
see also HIV infection
alcohol abuse, macrocytosis 96
alkylating agents
secondary AML with polycythaemia 489
therapy-related myeloid neoplasm induction 390
AML see acute myeloblastic leukaemia (AML) all-trans-retinoic acid (ATRA), acute promyelocytic leukaemia 314, 323, 325
alpha heavy chain disease (immunoproliferative small intestinal disease) 640
alpha naphthyl acetate esterase (ANAE) 297
acute hypergranular promyelocytic leukaemia 297
AML 297
AML (monoblastic) with t(9;11)(p22;q13) 333
AMML 361
chronic lymphocytic leukaemia 601
hypergranular promyelocytic leukaemia 319
alpha naphthyl butyrate esterase (ANBE) 297
AML see acute myelomonocytic leukaemia (AMML)
alphamidosis 737
amyloid 720
bone marrow aspirate 720–721, 723
histological sections 720, 722
blast cells(s) (cont’d)
chronic eosinophilic leukaemia, not otherwise specified 475, 500
chronic myeloid leukaemia, BCR-ABL1 positive accelerated phase 436, 437, 438
blast crisis 440, 441–443, 444, 445, 448–450
chronic myelomonocytic leukaemia 513–520, 523
diagnostic percentage 512, 512 definition 21
dysgranulopoiesis 235
essential thrombocythaemia 466, 471
granular see granular blast cells
granulocytic differentiation 362, 363
hypergranular promyelocytic leukaemia 319, 324
juvenile myelomonocytic leukaemia 537–539
MDS 209, 228, 234, 235
cell marrow aspirate 213–214, 225–227
dysplasia morphology 189, 190, 191, 194, 196, 199, 200
dysplastic promyelocytes vs. 231, 232, 233
histology 237
immunohistochemistry 246
morphological criteria 214, 230–237, 237
myelogram 225–227
promyelocytes vs. 231
subclassification 214, 237
morphological characteristics 558
myelodysplastic/myeloproliferative neoplasms 511
myeloid nature 226–227
myeloperoxidase stain 226–227
nucleus 289
percentage determination 17, 226–227, 376
plasma cell leukaemia 716, 718
primary myelofibrosis 473, 476, 479
pseudopodial extensions 231
blastic plasmacytoid dendritic cell neoplasm 400, 401, 402–403
hypergranular promyelocytic leukaemia 319, 324
refractory anaemia with excess of blasts 263
refractory anaemia with excess of blasts type 2 229, 236, 266
T-cell leukaemia/lymphoma 668
therapy-related acute erythroid leukaemia 390
therapy-related AML 391, 393, 396, 397
thyroid hormone inhibitor therapy, effects of 450
undifferentiated small cell carcinoma of the lung vs. 754
see also individual types
blast cell count 289
AML 289
cells to exclude 291, 292–293
cells to include 289–293
AML, not otherwise specified 294
automated analysers 403–404
chronic myelomonocytic leukaemia 519–520, 520, 521, 522
MDS 225, 232
peripheral leukaemias 294
blastic NK cell lymphoma see blastic plasmacytoid dendritic cell neoplasm
blastic plasmacytoid dendritic cell neoplasm 397–400
bone marrow aspirate 400, 401, 402–403
blastoid mantle cell lymphoma 627, 636
blasts as percentage of all nucleated cells (ANC), MDS 226–227
blasts as percentage of non-erythroid cells 226–227
bledred erythrocytes 128
blebs
MDS 210
megakaryoblasts 62
peripheral blood film 43
blaster cells see vesiculated cells
blood cytomorphology 26–78
number of cells in 26
blood cells 1–87
red see erythrocyte(s)
white see leucocytes
blood count
acute lymphoblastic leukaemia 554
chronic lymphocytic leukaemia 597–598, 673
chronic myeloid leukaemia, BCR-ABL1 positive 423–424, 486
follicular lymphoma 625
hair cell leukaemia 613
hair cell leukaemia variant 618
MDS 185
MDS associated with isolated del(5q) 266, 277
hyperferritinemia 748–749
polycythaemia vera 455
prolymphocytic leukaemia 610
refractory anaemia with excess of blasts 261–262
refractory anaemia with ring sideroblasts 185
splenic marginal zone lymphoma 621
Waldenström macroglobulinaemia 638
see also peripheral blood film, individual cell counts
blood transusions
erythrocyte dimorphism 109, 111, 170
rectum carcinoma 170
sickle cell crisis 172
B-lymphoblastic leukaemia/lymphoma 553
B-lymphoblastic leukaemia/lymphoma, not otherwise specified 554–569, 572–574
B-lymphoblastic leukaemia/lymphoma with hypodiploidy 577, 577, 578
B-lymphoblastic leukaemia/lymphoma with hypodiploidy 574
B-lymphoblastic leukaemia/lymphoma with recurrent cytogenetic alterations 574
B-lymphoblastic leukaemia/lymphoma with t(1;19) (q23;p13.3) 575
B-lymphoblastic leukaemia/lymphoma with t(5;14) (q31;q32) 575
B-lymphoblastic leukaemia/lymphoma with t(9;22) (q34;q11.2) 574, 574–575, 575, 576, 583
B-lymphoblastic leukaemia/lymphoma with t(12;21) (p13;q22) 575
B-lymphoblastic leukaemia/lymphoma with t(1;19)(q23;p13.3) 575
B-lymphocytes
differential count 6
HIV infection 273
maturational switch 31–32
multiple myeloma 686
boat-shaped cells (cigar-shaped cells) 121, 122, 123
bone marrow aplasia 155–160
aspirate see bone marrow aspirate
biopsy see bone marrow biopsy (histology)
41 cells 1–87
in chronic inflammatory states 728–736
cytomorphology 26–78
fibrosis see bone marrow fibrosis
gelatinous transformation 164, 729–730, 731, 732
granulomatosis 68, 730–733, 733, 734
hypercellularity
atypical chronic myeloid leukaemia 530, 536
chronic myeloid leukaemia, BCR-ABL1 positive 427, 428
chronic myelomonocytic leukaemia 521, 523
polycythaemia vera 455–456, 456, 457
hypocellularity
primary myelofibrosis 473, 477, 478, 479, 480
refractory cytopenia 346
hypoplasia 155–160
in infections 728–736
necrosis 161–164, 165
acute 728–729, 732
parvovirus B19 infection 160
non-haematological neoplasm metastases 16, 736–755
bone marrow aspirate vs. biopsy 744
cell size 747
cytochemistry 749
differential diagnosis 734, 735, 737, 747, 748–749, 749–750
event sequence/cascade 741
growth factors, tumour-produced 741
incidence 744
leucerythroblastotic picture 744, 745
morphological characteristics 747–750, 748
peripheral blood changes 744–747
tumour cells 747–749
tumour-specific morphological characteristics 750–755
vacuoles 749
percentage of total body weight 7
reactive changes see reactive bone marrow changes
bone marrow aspirate 7, 12–18
acute lymphoblastic leukaemia 559, 559–565
acute megakaryoblastic leukaemia 377–378
acute panmyelosis with myelofi brosis 384, 387
acute promyelocytic leukaemia, microgranular variant 325
AML see acute myeloid leukaemia (AML)
AML, not acute myeloid leukaemia (AML) 358, 359–363
amyloidosis 720–721, 723
anaemia 145–165
aplastic anaemia 161
atypical chronic myeloid leukaemia 533, 534, 536, 537, 539
blastic plasmacytoid dendritic cell neoplasm 400, 401, 402–403
bone marrow metastases 744, 747–750, 748
Burkitt lymphoma 643, 649
chronic eosinophilic leukaemia, not otherwise specified 500, 501
chronic lymphocytic leukaemia 596
chronic myeloid leukaemia, BCR-ABL1 positive accelerated phase 433, 435–437, 439
chronic phase 424, 427–433, 428–435
chronic myelomonocytic leukaemia 521–522, 523–527, 529
chronic neutrophilic leukaemia 452
congenital dyserythropoietic anaemia 165, 166, 167
cytomorphology 33–78
diagnostic errors 14, 17
essential thrombocythaemia 461–462, 463–469
Fanconi anaemia 161
film preparation 12
follicular lymphoma 625, 630
haem cell leukaemia 614, 616, 618, 620
haem cell leukaemia variant 619, 622
histological examination 16, 20
HIV infection 273
Hodgkin lymphoma 645–646, 654, 655, 656
hypergranular promyelocytic leukaemia 314–319, 316–324
infectious mononucleosis 42
inflammatory foci 79
iron deficiency anaemia 145–148
iron stores evaluation 145, 146
iron myelomonocytic leukaemia 539, 541
large granular lymphocytic leukaemia 654
lymphplasmacytic lymphoma 653
mantle cell lymphoma 626
maximum volume aspirated 12
MDS see myelodysplastic syndrome(s) (MDS)
megablastic anaemia 145, 149–155, 153, 154
microcytic anaemia 145–149
microscopic examination 12–17
cellularity evaluation 12, 14, 15
high power examination area selection 14, 17
large cell cytological assessment 14, 15, 16
maturation curve 16–17, 18
mitotic figure percentage 17
process 12–14, 13
representative sample evaluation 12, 13
multiple myeloma see multiple myeloma
myelogram (differential count) 13, 17, 18
obtaining 12
plasma cell leukaemia 716, 718
poly巡查aemia vera 455–456, 456–457
pre-microscopic examination 12
primary myelofibrosis 473, 477, 478, 479, 480
prolymphocytic leukaemia 610, 613
pure red cell aplasia 160, 162, 163
refractory anemia 252
refractory anemia with excess of blasts 262
refractory anemia with ring sideroblasts and
thrombocytopenia 544–545, 546, 547, 548
refractory cytopenia with multilineage dysplasia 228
report 17, 19
Sézary cells 667
splenic marginal zone lymphoma 622
staining 12
systemic mastocytosis 479, 481, 482, 483, 484
T-cell prolymphocytic leukaemia 650
thalassaemia 148, 149, 150, 151
Waldenström macroglobulinaemia 16, 639, 640, 641, 642
see also individual cell types
bone marrow biopsy (histology) 18, 20
atypical chronic myeloid leukaemia 537, 539
Burkitt lymphoma 643
chronic lymphocytic leukaemia 605–606
chronic myeloid leukaemia, BCR-ABL1 positive
accelerated phase 437, 439
chronic phase 430–433
chronic myelomonocytic leukaemia 522, 529
haery cell leukaemia 616, 618
hyperplastic T-cell lymphoma 670
indications 18
mantle cell lymphoma 626
MDS 203
non-haematological neoplasms metastases 744
poly巡查aemia vera 453, 454
primary myelofibrosis 480
prolymphocytic leukaemia 613
Sézary cells 667
splenic marginal zone lymphoma 622
T-cell prolymphocytic leukaemia 650
see also individual cell types
bone marrow fibrosis
acute conditions causing 747
bone marrow metastases 744, 747
breast cancer 753, 756
poly巡查aemia vera 455
tyrosine kinase inhibitor therapy 450
bone marrow histology see bone marrow biopsy
(biopsy)
Bordetella pertussis 38
breast carcinoma
bone marrow metastases 753–756, 755
lump node metastases 761
breccelosis 721, 722
budding erythrocytes 128, 128
buffy coat, peripheral blood film 6
bull's eye cells seen target cells
Burkitt lymphoma 590, 640–643
AIDS patient 652
bone marrow aspirate 643
bone marrow histology 643
bone marrow infiltration 649
development 589
general analysis 643
immunophenotype 643
leukaemic (endemic) form 646–653, 650, 676
starry-sky appearance 643
subtypes 640
burst cells seen echinocytes
burst-forming unit erythroid (BFU-E) 5, 91
burst-forming unit megakaryocyte (BFU-MK) 5
Cabot rings 25, 131–132
Candida albicans (histology) 477, 478, 479, 480
Candidiasis 727, 729
Candida albicans
Calcium, renal, anaemia, bone (CRAB), multiple
myeloma 682
CALR mutation 548
Candida albicans infection 727, 731, 762
candidiasis 727, 731, 762
carcinocytoma 744–747, 745, 746–747, 763
CCND1 gene, mantle cell lymphoma 588
CD2, acute promyelocytic leukaemia 327
CD4-positive, CD8-positive haematodermic
neoplasm see blastic plasmacytoid dendritic cell
neoplasm 589
CD7, AML 299
CD33, AML 299
CD34-positive cells
acute lymphoblastic leukaemia 568
AML 299
CD66, acute promyelocytic leukaemia 323
CD71, acute erythrocytosis 370, 374
CD18, multiple myeloma 706
CD33, AML 299
CD34-positive cells
acute lymphoblastic leukaemia 568
AML 299
CD66, acute promyelocytic leukaemia 323
CD71, acute erythrocytosis 370, 374
CD18, multiple myeloma 706
CERPs gene 336
cellular haemoglobin concentration mean (CHCM)
93, 139, 140
central nervous system
acute lymphoblastic leukaemia 553, 554
Burkitt lymphoma 648
lymphoblasts in 553, 554
centroblasts 589
follicular lymphoma 623
centrocytes
cytosplasm 625, 629
follicular lymphoma 623, 625, 629, 630
formation 589
nucleus 625, 629
cerebrospinal fluid (CSF)
Burkitt lymphoma 648
diffuse large B-cell lymphoma, not otherwise
specified 644
follicular lymphoma 632
plasma cell leukaemia 719
CFC-MYH11 fusion gene 301
Index 771
Charcot-Leyden crystals 312, 500
chronic eosinophilic leukaemia, not otherwise
specified 500
eosinophilia 497
neoplasms with rearrangement of PDGFRα 504
chloroacetate esterase (CAE) 297
acute lymphoblastic leukaemia 297
AML 295, 297
AML with eosinophilia and inv(16) or t(16;16) 312
chloroma see myeloid sarcoma
chromatin 23
immature 23
see also individual cell
chromia 94
chromocentres 23
chronosomal translocations, multiple myeloma 709
chromosome 3 inversions 247–248
chronosome 3 translocations 247–248
chronosome 9 translocations, CML 423
chronosome 16 inversion 300–301
chromosome 22 translocations, CML 423
chromosome translocation (8;14)(q24;q32) 643
chronosome translocation (9;22)(q34;q11.2) 423, 572, 574
chronosome translocation (11;14)(q13;q32) 709
chronosome translocation (14;18)(q32;q21) 625
chronosome translocation (15;17)(q22;q12) 314
chromosome translocation (16;16)(p13;q22) 301
chronic eosinophilic leukaemia, not otherwise
specified (CEL, NOS) 475, 497–500
bone marrow aspirate 500, 501
eosinophil dysmorphum 500
pathological effects 500
peripheral blood film 500
WHO diagnostic criteria 500
chronic haemolytic anaemia, parvovirus B19 infection
159–160
chronic lymphocytic leukaemia (CLL) 590, 590–608
AML during course of 608
atypical 602
with autoimmune haemolytic anaemia 595, 596,
598, 673
autoimmune phenomena complicating 598
B lineage 590–608
esential thrombocytopenia and 469
blood count 597–598, 673
bone marrow biopsy 604–606
bone marrow infiltrate 594
bone marrow morphology 595, 596, 597, 598, 599,
604–606
cytochemistry 601
cytograms 594
cytoplasmic inclusions 601
diagnostic criteria 591, 594
differential diagnosis 39, 607
disease evolution 607–608
follicular lymphoma vs. 593, 596, 623
 genetic analysis 607
 genetic influence 593
 immunophenotype 606–607
 incidence 593
 infiltration patterns 606
lymphocytes in see lymphocytes
mixed cell type 590, 602–604, 602–606
immunophenotype 607
morphological heterogeneity 601–604, 603
PANDA classification 406
peripheral blood morphology 594, 598–604
prolymphocytic transformation 604, 607, 608
small lymphocyte lymphoma vs. 595, 602
staging systems 597
 symptoms 593–594
chronic myeloproliferative disorder of NK cells 655, 656
chronic myeloid leukaemia (CML) 511–530
atypical see atypical chronic myeloid leukaemia (aCML)
BCR-ABL1 positive see chronic myeloid leukaemia, BCR-ABL1 positive
blast flag 406, 486
historical aspects 422
PANDA classification 406
chronic myeloid leukaemia, BCR-ABL1 positive 422–450
accelerated phase 423, 428, 433–440, 487
automated instrument printout 487
bone marrow biopsy 437, 439
cytochemistry 437
diagnostic criteria 435–440, 439
dysplasia 436
dysplasia 436, 436
peripheral blood 437, 439
atypical chronic myeloid leukaemia vs. 530, 531, 537
blast crisis 423, 440, 441, 446, 448
basophilic 440, 446, 447
cytchemistry 440, 446
diagnostic criteria 439, 440
erthyroid 440, 444
granulocytic 442
immunophenotyping 440, 448
lymphoid 440, 446, 448, 448, 449, 450
megakaryocytic 440, 444, 445, 446, 446
mixed populations 446, 447, 450
myeloid 440, 442, 443, 447
myelomonocytic 440
pure monocytic 440, 443
T-lymphoid 446, 448, 449
chronic myelomonocytic leukaemia vs. 522
chronic phase 423–433
blood count 423–424, 486
bone marrow aspirate 424
bone marrow biopsy 430, 433
bone marrow morphology 427–433, 428–434
diagnostic criteria 424
peripheral blood morphology 424, 424,
424–427, 425, 426
natural history 423, 427
p190 423
p210 423
p230 423
at presentation 486
chronic myelomonocytic leukaemia (CML) 261, 511–530
acute monocytic leukaemia vs. 525
AML, evolution to 512, 513
AML vs. 526, 530
AMML vs. 525
atypical chronic myeloid leukaemia vs. 534
atypical evolution 543
automated instrument output 529, 549
bone marrow aspirate 521–522, 523, 524, 525, 526, 527, 529
bone marrow biopsy 522, 529
bone marrow precursors dysplasia 522, 528, 529
chronic myeloid leukaemia, BCR-ABL1 positive vs. 522
clonal alterations 512
cytochemistry 515, 521–522, 522
diagnostic criteria 511–512, 512, 518–520, 545
differential diagnosis 522–530, 525, 526
extramedullary localisation 513
immunohistochemistry 529
immunological anomalies 513
immunophenotyping 512–513
incidence/prevalence 513
leukaemic evolution 527
MDS type 522
MDS vs. 527–530
myeloproliferative neoplasm type 522
neutrophil monocyte ratio 521
peripheral blood 513–520, 514, 515, 516, 517, 528
from preceding MDS 530
presenting symptoms 513
prognostic aspects 522–530
molecular features 527
1q7 isolated isochromosome 512
subtypes 512
survival 513
systemic mastocytosis 512
terminal phase 544
chronic myelomonocytic leukaemia 1 (CMML-1) 512, 527
chronic myelomonocytic leukaemia 2 (CMML-2) 512, 512
chronic myelomonocytic leukaemia with eosinophilia 512, 513
chronic neutrophilic leukaemia (CNL) 450–452, 451, 452
bone marrow aspirate 452
diagnosis 450, 452
leukaemia reaction vs. 727
peripheral blood film 450, 452
cigar-shaped cells (boat-shaped cells) 121, 122, 123
clasmacytosis 228
Burkitt lymphoma 647
clear cell carcinoma of the kidney 756
CML vs. chronic lymphocytic leukaemia (CLL)
clonal eosinophils 495
causes 496
cloverleaf cells (flower cells) 661–662, 663, 664
CML vs. chronic myeloid leukaemia (CML)
CMML vs. chronic myelomonocytic leukaemia (CMML)
codocytes see target cells
cold autoimmune haemolytic anaemia
bone marrow aspirate 160
erthyroid agglutination 140, 169
erthyroid hyperplasia 160
infectious mononucleosis 168
cold haemagglutinin disease, red cell agglutinates 134, 136
colon cancer, carcinoctyaemia 763
colon-forming unit erythroid (CFU-E) 5, 91
colon-forming unit granulocyte (CFU-G) 5
colon-forming unit granulocyte, erythroid, macrophage, megakaryocyte (CFU-GEMM) 4
colon-forming unit granulocyte/macrophage (CFU-GM) 4, 5
colon-forming unit megakaryocyte (CFU-MK) 5
colon-forming unit monocyte/macrophage (CFU-M) 5
colon-forming units (CFU) 4, 5
colour index 93, 94
common T-acute lymphoblastic leukaemia 571
compound heterozygotes for haemoglobin C and
haemoglobin G
intra-erythrocyte crystals 132–133
sickle cells 112, 121
target cells 110, 112, 122
genital anaemia, erythrocyte dimorphism 170
congenital dyserythropoietic anaemia (CDA) 165
basophilic stippling 167
bone marrow aspirate 165, 166, 167
peripheral blood film 163
congenital Haemoglobin C syndromes 134
congenital sideroblastic anaemias 148
Congo red stain, amyloidosis 720, 722
Cooley anaemia (thalassaemia major) 148
see also beta thalassaemia major
cord blood 4
core binding factor (CBF) 300
mutations 300–312
Coulter impedance method 94
CRAB (calcium, renal, anaemia, bone), multiple myeloma 682
cretated cells see echinocytes
cryoglobulin 7, 10
cytokines
leukaemic reaction 727
megakaryocytopenia 5
cytopenia
chronic lymphocytic leukaemia 597, 673
HIV infection 271
MDS 185
cryoglobulin 19, 24
see also individual cell types
cytopenic inclusions 25
cytotoxic suppressor T cells 651–652
dacrocytes 26, 107, 124, 127, 129
MDS 186, 187
primary myelofibrosis 467, 472
Danelli reaction, multiple myeloma 690
dasatinib 448, 450
second neoplasm risk 450
DEK-NUP214 330, 336
del(5q) 248
del(11q)
chronic lymphocytic leukaemia 607
iron deposition 248
del(13q) 607
del(17q)
AML 248, 348
chronic lymphocytic leukaemia 607
MDS 248, 348
del(20q) 248, 270
diffuse large B-cell lymphoma 590
development 589
leukaemic phase 675
diffuse large B-cell lymphoma, not otherwise specified
(DLBCL, NOS) 589, 640, 643, 644, 645, 675
immunophenotype 640
Di Guglielmo’s disease (syndrome) 366, 368
dispersion indices, erythrocytes 140–141
disseminated intravascular coagulation 744
Döhle bodies 25, 31
MDS 190, 193, 222
double extramedullary stain
AMML 297–298, 299, 361
chronic myelomonocytic leukaemia 522
Down syndrome 396
myeloid proliferations and 396–397
Dutch er bodies, plasma cells 21
multiple myeloma 693, 698, 701, 718
nucleoli vs. 693, 718
plasma cell leukaemia 719
dwarf megakaryocyte, CML, BCR-ABL1 positive 427–428, 429, 433, 434
dyserythropoiesis
acute erythroid leukaemia 366, 372, 373
atypical chronic myeloid leukaemia 530–534
chronic myelomonocytic leukaemia 522
chronic myelomonocytic leukaemia diagnostic criteria 512
leukaemia classification, historical 287–288
MDS
blast cell subclassification 214, 237
classification 183–184
fungal infections 727, 734, 742
Fusarium spores 742
gametocytes, malaria 729, 730
gamma heavy chain disease 640
Fusarium spores 730
GATA1 gene mutations 396, 397
Gaucher cells 21, 63
gene expression profiling, multiple myeloma 711
giants
erythroblasts, MDS 211, 218
erythroblasts, MDS
neutrophils 33
platelets 26–28
essential thrombocytopenia 460
MDS 196, 200, 201
GluCTP deficiency, haemolytic crisis 107–108
granulocytes, cytoplasmic 24
AML with granulocytic maturation 347, 355
AML with myelodysplasia-related changes 343, 345
AML without granulocytic maturation 346
AML with granulocytic maturation 347, 355
AML with myelodysplasia-related changes 343, 345
chronic myeloid leukaemia, BCR-ABL1 positive 425
differentiation 48
dysplasia
AML with granulocytic maturation 343, 356
MDS 195, 203
immature
automated analysers 403–404
chronic myeloid leukaemia, BCR-ABL1 positive 424–426
MDS 190, 195–199
megablastosis 153
peripheral blood film 8
granulocyte growth factors 251
granulocyte-macrophage colony-stimulating factor (GM-CSF), JMML diagnosis 540
chronic myeloid leukaemia, BCR-ABL1 positive
accelerated phase 433, 435
case 427, 430, 430–433, 431, 432–433
doughnut appearance 223
dysphosphorylase 55
gigantism 35
MDS 199
in an inappropriate position 237
nucleus 23
granulocytic sarcoma see myeloid sarcoma
granulocytic series
AML with recurrent genetic abnormality (t(6;9)) 134
bone marrow aspirate 44–51, 48, 49–54
chronic myeloid leukaemia, BCR-ABL1 positive
accelerated phase 438
hyperplasia 427, 429
granulocytic growth factor effects 251
mature 43, 48–49
MDS 223
bone marrow aspirate 206–210, 221–229
dysplasia 229
hypogranularity 224
megakaryocytic anaemia 150, 157
megakaryocytic dysplasia 153, 157
morphology 44–51, 48, 49–54
multiple myeloma 687
Waldenström macroglobulinaemia 640
se a l s o ind iva l cell types
granulomas, bone marrow 68, 730–733, 733, 734, 735
granulopoiesis
abnormal see dysgranulopoiesis
chronic myeloid leukaemia, BCR-ABL1 positive 427, 429
grey platelet syndrome 27
growth factor treatment
granulocytic precursor dysmorphism 55
neutrophil dysmorphism 28, 31, 32, 33
Gompertz's shadow see smear cells
haematocrit (Hct) 92–93
anaemia screening, false negatives 93
artefacts 93
polychromatia vera 453, 455
haematogones 568, 570
haematological cytology
single cell type terminology 21
diff erential count 18–21
haematological cytomorphology
cell shape 21–22
cell size 21–22
feature descriptions 19–20
general characteristics 21, 22
morphological abnormalities 19
morphological interpretation 19
principles 18–25
qualitative assessment 19
semantics 20
single cell type terminology 20
see a l s o in d iva l cell types
haemolysis, iron-deficient erythropoiesis 142
haemoglobin C
intra-erythrocyte crystals 132, 133
irregularly contracted cells 116
target cells 110, 111
haemoglobin distribution width (HDW) 140, 141
haemoglobin F 539
juvenile myelomonocytic leukaemia 540
haemoglobin Hammersmith 116, 113
haemoglobin H disease 133, 134, 174
macroglobulinaemia 174
haemoglobin H inclusions 133–134, 134
haemoglobinisation defects 106–108, 108
MDS 205, 217
haemoglobin S 121, 123
haemoglobin S-Oman 121
haemoglobinuria, paroxysmal nocturnal 155
haemolsysin, haemoglobin estimates 93
haemolytic anaemia
aplastic crisis 155
autoimmune see autoimmune haemolytic anaemia
bone marrow aspirate 155, 160
haemophagocytic lymphohistiocytosis see haemophagocytic syndrome
haemophagocytic syndrome 733
malignant melanoma vs. 737
morphology 62, 63, 733, 747, 738
neoplasms and 608, 733
virus-associated 160–161, 164
haemophagocytosis
definition 160
haemophagocytic syndrome 733, 738
by leukaemic cells 363
macrophages 62, 160, 164
plasma cells, multiple myeloma 708
haemopoiesis
biology 1–6
bone marrow metastases 744
haemoglobin H disease 174
historical aspects 1
monophyletic (unitary) theory 1, 2
stem cells see haemopoietic stem cells
haemopoietic cells
differentiation 18–19, 26
evolution 18–19
mature 19
migration 19
proliferation 18
see a l s o in d iva l cell types
haemopoietic compartments 3
daemon of cell growth 18–21
microenvironment and 2–4
signals 4
single-cell imaging 4
haemopoietic progenitors 5
haematopoietic potential 4
definition 4
morphology 4, 26
multilineage potential 4
unilineage potential 4
haemopoietic stem cells 1–2
asymmetric mitosis 1
immunophenotypic markers 2
mobility 2–4
morphology 2, 3, 4, 26
multipotent 1
peripheral blood 26
properties 1, 3
self-renewal capacity 1, 3
stable number, maintenance of 1
mature T-cell acute lymphoblastic leukaemia 571
mature T-cell neoplasms 587–680
classification 587–589
clinical presentation 649
definition 587–589
diagnosis 649
reactive lymphocytosis vs. 649
types 589, 649–668, 656
see also individual neoplasms
May-Grünwald-Giemsa stain 7
May-Hegglin anomaly 25
MCH see mean corpuscular haemoglobin (MCH)
MCHC see mean cell haemoglobin concentration (MCHC)
McLeod syndrome 120
M component (monoclonal component) see paraprotein
MCV see mean cell volume (MCV)
mean cell haemoglobin (MCH) 139–140
calculation 139–140
false elevated 139–140
mean cell haemoglobin concentration (MCHC) 93, 95, 138–139
calculation 138
false elevated 139–140
impedance methods 139
as instrument calibration indicator 95, 139
mean cell volume (MCV) 92, 94–95
anaemia classification 95
false increases 140
 genetic control 95
increased 95
MDS 185
megablastosis 376–377
minimal/maximum values 94
overestimation 94
polychromatophilic cells 453
reduced 95
mean corpuscular haemoglobin (MCH) see mean cell
haemoglobin (MCH)
mean corpuscular volume (MCV) see mean cell
volume (MCV)
mean platelet volume (MPV), MDS 185
mean platelet volume (MPV), MDS 185
medullblastoma, metastases 756
megakaryoblasts
acute megakaryoblastic leukaemia 378, 380, 380, 381, 382
AML 289, 291, 292
bone marrow aspirate 62, 69
chronic myeloid leukaemia, blast crisis 440, 444, 445, 446
MDS 250
morphology 62, 69
nucleus 69
megakaryocytes(s)
acute megakaryoblastic leukaemia 380
AML with t(3;3)(q21;q26.2) 336, 337, 338
atypical chronic myeloid leukaemia 533, 534, 536, 545
bone nuclei 84–67, 75
chronic neutrophilic leukaemia 453
clusters, essential thrombocythaemia 462, 464
CML, BCR-ABL1 positive accelerated phase 439
blast crisis 444, 446
chronic phase 427–428, 429, 433, 434
cytosplasm 64
liberation 74
differentiation 69

dysmorphism
elemental thionin 466, 470
essential thrombocythaemia 466, 470
megakaryoblastic anaemia 158
dysplasia
atypical chronic myeloid leukaemia 34
refractory thrombocythemia 257, 257
eccentric nucleus 73
essential thrombocythaemia 461, 462, 462–464,
466–470
giant dysplastic 243
gigantism
essential thrombocythaemia 463, 463, 464, 465,
458, 469, 471
megakaryoblastic anaemia 158
megablastosis 153, 158
nuclear anomalies 239, 247, 248
pepsioid 249
saliency slice appearance chromatin 242
separate nuclei 242
MDS associated with isolated del(5)(q) 244, 245,
246, 266, 267
MDS/MPN-U 545
MDS/MPN-U with t(17p) 545
MDS with del(5)(q) and JAK2 mutation 545
megakaryoblastic anaemia 150
multiple myeloma 687
nucleus detachment 74
platelet demarcation zones 72
polychromatophilic 453, 454, 454–457, 457, 459
primary myelofibrosis 473, 477, 478
5q- syndrome 245
non-lobated/hypolobated nucleus 246
refractory anaemia 244
refractory anaemia with excess of blasts 263
refractory anaemia with excess of blasts type 1
239
refractory anaemia with excess of blasts type 2
248
refractory anaemia with ring sideroblasts and
thrombocytosis 545, 545, 546
refractory cytopenia with multilineage dysplasia
204
dysplasia 243
tyrosine kinase inhibitor therapy, effects of 450
megakaryocyte-erythroid progenitor (MEP) 5
megakaryocyte progenitors (precursors) 5, 69
chronic myeloid leukaemia, BCR-ABL1 positive 444
essential thrombocythaemia 467
growth factors 5
types 3
megakaryocyte series
bone marrow aspirate 62–67, 69, 69–75
MDS 227–230, 237
dysmorphism 196, 201

dysplasia morphology 196, 200, 201, 202,
227–228, 238–250
morphology 62–67, 69, 69–75
megakaryocytosis 462
megakaryocyte(s) 104
basophilic
megakaryoblastic anaemia 150, 152, 157
pernicious anaemia 153, 293
bone marrow aspirate 150
pernicious anaemia 154
polychromatic 150, 155
megakaryoblastic anaemia
acute erythroid leukaemia vs. 376–377
anti-cancer drug-induced 155, 159
blood abnormalities 104, 105
bone blood marrow 150, 152
bone marrow aspirate 145, 149–155, 153,
154
co-existing nutritional deficiency 154–155
diagnosis 169
diagnostic errors 154–155
dysmorphism 152, 169
erthrythrocytosis 109
 ineffective myelopoesis 153, 159
macrocytosis 104, 105
macrophages 153, 159
MDS vs. 206
mitotic figures 151
red cell distribution width 104, 105
vitamin therapy effects 145–155
megakaryoblastic erythropoiesis
macro-ovalocytes 105, 128
MDS 206
megakaryoblastoid maturation, MDS 218
megakaryoblasts 95, 376–377
blood abnormalities 104, 105
bone marrow aspirate 152
erythroid poiesis phase 150, 154
labatory investigations 145
macrocytosis 104
mean cell volume 104
as pancytopenia 153
melanoma
bone marrow metastases 756
haemagoblastic syndrome vs. 737
memory B lymphocytes 589
merosite, malaria 729
metachromasia 7
metamyelocytes
automated analysers 404
basophil 31
bone marrow aspirate 50, 51, 51, 57
chronic myeloid leukaemia, BCR-ABL1 positive
425, 429, 431
MDS 223, 235
megakaryoblastic anaemia 152, 156, 157
megakaryoblastosis 153
morphology 50, 51, 51, 57
neutrophil
chromatin 49
chronic myelomonocytic leukaemia 513
morphology 49, 49
methylene blue staining 7
methyl green pyronine 298
Mexican hat cells see target cells
microangiopathic haemolitic anaemia, bone marrow
metastases 744, 745
microarray analysis, multiple myeloma 711
microcytes 94, 102, 102, 103
hypochromic cells and 142, 174
primary myelofibrosis 472

Index 779
microcytic anaemia
bone marrow aspirate 145–149
erythropoiesis 94–95
mean cell volume 95
reticulocyte count 98
microcytic erythrocytes, refractory anaemia with ring sideroblasts 257
microcytosis 102, 102–103
haemoglobin H disease 174
haemoglobin synthesis defect 95, 102
hypochromia 102, 104, 170
mean cell volume 102
polycythaemia vera 455
rectum carcinoma 170
microerythroblasts 149
microhypo ratio 142
haemoglobin H disease 174
micromegakaryocytes 227–228
acute megakaryoblastic leukaemia 378
AML with t(3;3)(q21;q26.2) 337
chronic myeloid leukaemia, BCR-ABL1 positive 244
chronic myelomonocytic leukaemia 523
MDS 196, 202, 227–228, 239, 240, 241
cytoplasmatic ratio 239
nucleus variations 240
refractory anaemia with excess of blasts type 1 241
therapy-related AML 391
therapy-related AML with myelodysplasia 394
therapy-related myelodysplasia 389
micrometastases, breast carcinoma 756
micronormoblasts, thalassaemia 148–149
micro-organisms, intra-erythrocytic 134, 135
microspherocytes 107, 114–115, 116, 123–124, 125, 126
abnormal ineffective erythropoiesis 107, 124
as artefact 124
mitotic figures
bone marrow metastases 749
Burkitt lymphoma 643, 647
chronic myeloid leukaemia, BCR-ABL1 positive 427, 431
MDS 238
mixed phenotype acute leukaemia (MPAL) 577–580, 579, 580, 581, 582
diagnostic criteria 577–579
B lineage 579
T lineage 579
MLL (mixed-lineage leukaemia) gene 329, 575
acute lymphoblastic leukaemia 572, 575
MLLT3-MLL fusion gene 529
monoblasts
acute monoblastic leukaemia 359, 364, 365, 366
neutrophil count 23
acute monoblastic leukaemia 368, 370
AML 289–291, 292
AML (monoblastic) with t(9;11)(p22;q23) 329, 332, 333
AML 358, 360
AML with eosinophilia and inv(16) 311
chronic myelomonocytic leukaemia 517, 521, 522, 525, 526
leukaemic evolution 527
erithrophagocytosis 371
mature monocytes 21, 517, 520
monoclonal B lymphocytosis 591, 595–597
monoclonal component (M component) see paraprotein
monoclonal gammopathies see plasma cell proliferative disorders
monoclonal gammopathy of undetermined significance (MGUS) 681, 682, 689
diagnostic criteria 683
multiple myeloma, progression to 681
monoclonal mast cell activation 484–485
monocytic(s)
acute monocytic leukaemia 361–363
AML (monoblastic) with t(9;11)(p22;q23) 329
AMML 360
chronic myeloid leukaemia, BCR-ABL1 positive 423
dysmyelopoiesis 518
chromatin 518
myelomonocytic leukaemia 513–520, 514–518, 521, 523–526, 528
dysplastic granules 513–515
dystrophism 516
nucleocytoplasmic ratio 514
peroxidase content 515
cyttoplasm 516
cytoplasmic granules 25
hair cell leukaemia 613
HIV infection 272–273
immature/acute/typical 291, 293, 293
chronic myelomonocytic leukaemia 513–520, 524, 526
morphology 513–513, 513–520, 517
in infective conditions 731
maturation stages 515, 517
morphology 517
bone marrow aspirate 51, 58
peripheral blood films 30, 32, 40, 42
nucleus 32
plasmacytoid 400
vacuoles 32
monocyte count, chronic myelomonocytic leukaemia 511, 513
monocyte/macrophage progenitors 5–6
monocyte/macrophage series 51–6
see also individual cells
monoytoid B-cell lymphoma see nodal marginal zone lymphoma
monocytosis
acute monoblastic leukaemia 415
chronic myeloid leukaemia, BCR-ABL1 negative 423
chronic myelomonocytic leukaemia 513, 517, 527–530, 529
mononuclear leukocytes 28
monosomy 7 248, 268, 539
Mott cell(s) 693, 695, 696, 696–698, 701, 733
bunch of grapes appearance 693
Mott cell myeloma 695
MPL gene mutations 458
MPL protein 5
MPN see myeloproliferative neoplasm(s) (MPN)
macroc, bone marrow metastases 744
mu heavy chain disease 590, 640
multiple myeloma 294, 681–711
amorphous material 684, 684–685, 685
blood count 684–686
bone marrow 686–687, 688–691
plasma cell percentage 686
clinical features 682–683
diagnostic criteria 683, 683
disease course/clinical picture 684
epidemiology 682–683
follow-up 686
general analysis 709–711
genetic predisposition 682
histology 706
historical aspects 681–682
immunophenotype 686, 706–709
incidence 682
MGUS, progression from 681
peripheral blood film 684–686
plasma cell leukaemia vs. 715
prognosis, morphology and 704–706
reactive plasmacytosis vs. 706
staging 682–683
subgroups 706, 709
therapy 704
see also plasma cell(s)
multiple myeloma with osteosclerosis 711–713
multipotent T-cell progenitors 6
ATF4 gene
Burkitt lymphoma 640, 643
leukaemic (endemic) form 640–643, 676
mycosis fungoides 664
myeloblasts
acute erythroid leukaemia 367, 368, 373, 375
AML with eosinophilia and inv(16) or t(16:16) 309
AML with t(8;21) 308
bone marrow aspirate 44, 48, 49, 50, 52, 54
chronomatin 44
chronic myeloid leukaemia, BCR-ABL1 positive 424
cyttoplasm 44, 48, 50
lymphoblasts vs. 554
morphology 44, 48, 49, 50, 52, 54, 558
nucleoli 44
nucleus 44
myelocytes
AML with eosinophilia and inv(16) or t(16:16) 309
AML with myelodysplasia-related changes 343
AMML with eosinophilia and inv(16) 311, 312
automated analysers 404
basophil 51
MDS 223
chronic myeloid leukaemia, BCR-ABL1 positive 224
accelerated phase 436
chronic phase 424, 425, 427, 431
cyttoplasm 48–49
eosinophil 498
morphology 51, 55, 56, 57
reactive eosinophilia 496
MDS 223
basophil 205
dysplasia 223
hypergranulation 225
hypergranulation 206
neutrophil 223
chronic myelomonocytic leukaemia 513
morphology 48–49, 50
nucleus 48
refractory anaemia with excess of blasts type 1 224
myeloid/myeloproliferative neoplasms (MDS/MPN) 184, 511–552
blood count 185
characteristics 511
classification 511
cytogenetic and molecular genetic analysis 511
diagnostic criteria 511
differential diagnosis 545
immunophenotypic abnormalities 511
PDXGR rearrangement 505, 508
see also individual neoplasms
myelodysplastic/myeloproliferative neoplasms, unclassifiable (MDS/MPN-U) 540
diagnostic criteria 540, 542
diagnostic features 543
exclusions 549, 541, 544
morphological features 540, 542
primary myelofibrosis (PMF) (cont’d)

hyperplasia 480
preleukemic phase 480
red cell morphology 467, 472, 473
teratocarcinoma differentiation 476
pro-B progenitors 6
proerythroblasts
prolymphocytic leukemia, BCR-ABL1 positive 427
prolymphoid transformation, CLL 533, 534, 535
prolymphocytes

cytoplasm 64, 191
CLL/PP characteristics 608
bone marrow morphology 610, 613
blood count 610
T-cell prolymphocytic leukemia 519–521, 524–526, 527, 528
granulocytic differentiation 363
morphology 21, 517, 520
nuclear characteristics 291
promyelocytes

AML 291, 292
AML with variant translocation t(11;17) with ZBTB16-RARA fusion gene 331
atypical chronic myeloid leukemia 532
automated analyzers 404
azurophilic granules 48
bone marrow aspirate 48, 49–54, 51, 57
chromatin 48
chronic lymphocytic leukemia 603
chronic myeloid leukemia, BCR-ABL positive accelerated phase 436, 438
blast crisis 440, 447
chronic phase 424, 425, 427, 430, 431
chronic myelomonocytic leukemia 521
cytoplasm 48
cytoplasmic basophilia 48
dysplastic see dysplastic promyelocytes
eosinophil 49–51
AML with eosinophilia and inv(16) 313
AML with eosinophilia and inv(16) 313
eosinophil 498
granules 49–51
morphology 55, 56
granulocytic differentiation 362
hypergranular promyelocytic leukemia 286, 291, 314, 315–317, 320–321
granules 314–318, 315
MDS 206–210, 223, 225–226, 229
blast cells vs. 231, 232
morphology 214, 225–226, 237
non-dysplastic maturation 205
megablastic anaemia 157
morphology 48, 49–54, 51, 57
MPN with hyper eosinophilia and rearrangement of PENGRA 503
neutral 50
normal vs. dysplastic 292
nucleus 48
refractory anemia with excess of blasts type 1 224
refractory anemia with excess of blasts type 2 229
proplatelets 458
prostate carcinoma, metastases 756, 757
protozoans 734, 743
Prussian blue staining, AML 298
P-selectin, megakaryocytes 473
pseudo-anemia 93
pseudo-Barr bodies (pseudo-drumsticks), MDS 186, 193
pseudo-Chediak-Higashi type granules 196
hypergranular promyelocytic leukemia 318, 319
pseudo-drumsticks (pseudo-Barr bodies), MDS 186, 193
pseudoelliptocytosis 128
pseudo-Gaucher cells 63, 428–430, 430
pseudoedoculopenia, platelet satellite 29
pseudo-erythroblastemia (transient abnormal myelopoiesis) 391, 397
pseudo-Pelger bodies, MDS 186, 189, 190, 191
pseudo-Pelger nucleus, MDS 192, 194
pseudo-Pelger type eosinophilia 500
pseudo-reticulocytosis 185
pseudosinuositids, hairy cell leukemia 616
pseudospherocytosis 114
pseudothrombocytopoiesis 11, 28, 29
pseudothrombocytosis 465
punctate basophilia see basophilic stippling
pure erythroid hypoplasia see pure red cell aplasia
(pRCA)
pure red cell aplasia (pRCA) 158, 598
bone marrow aspirate 160, 162, 163
erthyropoiesis arrest 158–160
pyknocyte 116
pyrimidine 5′-nucleotidase deficiency 129–130
5q- syndrome

dysmegakaryopoiesis 244, 246
megakaryocytes 245
Rai system, chronic lymphocytic leukemia staging 597
RAS gene mutation 512
RBMI/MLL fusion gene 336
reactive bone marrow changes 727–767
in infection 727–736
non-haematological conditions 727–736
reactive hypereosinophilia 496, 497, 498
causes 496
lymphoid neoplasms 495, 558
pathological processes 495
reactive lymphocytosis

mature T cell neoplasms vs. 649
peripheral blood, in infection 38, 39, 40, 727
reactive monocytosis 530
reactive plasmacytosis 716–720
recurrence 722
conditions associated with 720
immunophenotype 720
inclusions 693
multiple myeloma vs. 706
plasma cell leukemia simulation 719
plasma cells 719, 722
real-time quantitative polymerase chain reaction (RT-PCR)

correct promyelocytic leukemia 314, 323
AML 300
AML with core binding factor gene mutations 301
rectal bleeding, acute severe 170
red blood cells see erythrocyte(s)
red cell count (RBC) 92
anaemia evaluation 93
red cell distribution width (RDW) 101–102, 140
anisocytosis 140
bone marrow metastases 744
MDS 185
red cells see erythrocyte(s)
red cell stacking see rouleaux formation
red marrow (haemopoietic marrow) 7
Reed-Sternberg cell 646, 655, 656
refractory anaemia (RA) 251, 252
asynchronous maturation 206, 218
bone marrow film 252
cytogenetic abnormalities 252
differential diagnosis 252
dyserythropoiesis 255
erthroid blast nuclei fragmentation 212
erthroidic multinucularity 210
erthroidy polymorphism 187
erthroid dysplasia 252, 253, 254, 255
erthroid hyperplasia 205, 253
erthroidy hyperplasia 212
megakaryocyte morphology 244
Snappr-Schnedl granules 693, 694, 699
sodium fluoride 297
solid tumour metastases 744
differential diagnosis 734
solitary plasmacytoma 711
South-East Asian ovalocytosis 128
spherocytes 112–115, 213–216, 128, 142, 171
irregularly contracted cells vs. 115–116
mean cell volume 112
spherocytic elliptocytosis 114, 114
spherocytic hereditary elliptocytosis 128
spherocytes 105–106, 107
mean cell haemoglobin concentration 105
sphero-ovalocytes 114, 128
spherochistocytes see microspherocytes
spiny cells see acanthocytes
spleen
haery cell leukaemia 616
splenic marginal zone lymphoma 622
T-cell prolymphocytic leukaemia 650
splenic B-cell lymphoma/leukaemia, unclassifiable 614
splenic diffuse red pulp small B-cell lymphoma 618
splenic marginal zone lymphoma (SMZL) 590, 621–623
blood count 621
bone marrow histology 622
cytoplasmic inclusions 628
geneic analysis 623
immunophenotype 622–623
morphismology 621–622, 624, 625, 626, 627, 628
splenic histology 621
with villous lymphocytes 621–623, 624, 625, 626, 627
splenic red pulp lymphoma 590
splenomegaly
large granular lymphocytic leukaemia 653
T-cell prolymphocytic leukaemia 649
spur cells see acanthocytes
squamous cell carcinoma, metastases 756, 758, 759
stem cell niche 2
stem cells, haemopoietic see haemopoietic stem cells
8p11 stem cell syndrome (8p11 myeloproliferative syndrome) 305
stomatocytes 116–118, 711
conditions seen in 116–117
stomatocytic elliptocytosis 128
storage cells
chronic myeloid leukemia, BCR-ABL1 positive 428–430
multiple myeloma 696
stress reticuloocytes 96, 97
sternal cells 75, 79
Sudan black B stain 298
AML 298
AML without granulocytic maturation 347
hypergranular promyelocytic leukaemia 319
surface membrane immunoglobulin (SmIg)
chronic lymphocytic leukaemia 388
lymphoproliferative disorders 588
prolymphocytic leukaemia 588
syndrome of anomalous chromatin condensation 194, 537, 539, 540
Sympex-XE-5000 system 142
erthrocyte fragments counts 143
reticuloocytes indices 144
systemic lupus erythematosus 733, 736
systemic mastocytosis (SM) 478
bone marrow aspirate 479, 481, 482, 483, 484
chronic myelomonocytic leukaemia and 512
diagnostic criteria 481
differential diagnosis 484
geneic alterations 484
haery cell leukaemia vs. 482, 484, 485
see also individual types
systemic mastocytosis with associated clonal non-mast haemaloietic neoplasms 481
T-acute lymphoblastic leukaemia (T-ALL) 571, 571, 572, 573
automated instrument output 584
geneic alterations 572
immunophenotyping 571–572
target cells 110–112, 122, 123
macrocystic 110
microcytic 110
morphology 110, 110, 111
tartrate-resistant acid phosphatase (TRAP) 388
hair cell leukaemia variant 619
prolymphocytic leukaemia 610
splenic marginal zone lymphoma 621
T-cell leukaemia/lymphoma 667–668, 668–672
T-cell prolymphocytic leukaemia (T-PLL) 649–651, 656
bone marrow morphology 650
clinical course 649
cytogram 659
geneic analysis 650–651
immunophenotype 650–651
morphology 649–650, 657, 658
variants 649–650, 659
TCL1 (T-cell leukaemia/lymphoma 1) oncogene 651
TCR gene rearrangements 572
teadrop cells see dacrocyes 
teadrop dyskaryocytes see dacrocyes
teniposide 390–391
terminal deoxynucleotidyl transferase (TdT) 568
thallasiaemia
basophilic stippling 129
bone marrow aspirate 148, 149, 150, 151
leptocytes 105
macrophages 148
red cell indices 94
target cells 110
see also beta thallasia major
thallasiaemia intermedia 148, 150
thallasiaemia major (Cooley anaemia) 148
see also beta thallasiaemia major
therapy-related acute erythroid leukaemia 390
therapy-related acute myeloid leukaemia (t-AML) 387–388, 391, 395, 397, 530
de novo disease vs. 388
with maturation and multilineage dysplasia 398
with myelodysplasia 393, 394, 396
myelodysplastic phase preceding 388
prognosis 388
recurrrent cytogenetic abnormalities 387–388
without maturation 392
therapy-related acute myeloid leukaemia with t(15;17) 394
therapy-related acute myelomonocytic leukaemia 395
therapy-related myelodysplasia 389
therapy-related myelodysplastic/myeloproliferative neoplasms (t-MDS/MPN) 387
therapy-related myelodysplastic syndrome (t-MDS) 266, 387–388, 390–391, 530
de novo disease vs. 388
prognosis 388
therapy-related myelodysplasia 389
therapy-related myelodysplasia/myeloproliferative neoplasms (t-MDS/MPN) 387
therapy-related myelodysplastic syndrome (t-MDS) 266, 387–388, 390–391, 530
therapy-related myeloid neoplasms 387–391, 388–398
de novo disease vs. 388
following alkylating agents 390
following topoisomerase II-interactive drugs 390–391
prognosis 388
subgroups 388–391
thesaurocytes see storage cells
thrombocytopenia
acute lymphoblastic leukaemia 554
atypical chronic myeloid leukaemia 533, 538
chronic lymphocytic leukaemia 597
chronic myelomonocytic leukaemia 529
hypergranular promyelocytic leukaemia 314
infection 727
MDS 185
poyctycyaemia vera 455
thrombocytopenic purpura (TTP) 124
thrombocytosis 185
refractory anaemia with ring sideroblasts 260
thrombopoiesis 744
thrombopoietin 5
thrombotic microangiopathy 124, 126
T-lymphoblastic leukaemia/lymphoma 553, 575–577
morphology 571, 572, 573, 575–577
T-lymphocytes, development 6
toposomerase II-interactive drugs 390–391
toxic granules 25
Toxoplasma gondii 743
thrombocytosis 734, 743
transforming growth factor beta-1 (TGF-beta1) 473
transient abnormal myelopoiesis (TAM, pseudoleukaemia) 391, 397
transferritin gene mutation 720
trisomy 8 270
trisomy 12 595, 595, 607
throphozaetes, malaria 728
Trepanosoma gambiense 743
trepanosomes 734, 743
Turk cells see plasmacytoid lymphocytes
type I neurofibromatosis, JMM and 540
tryosine kinase, aberrant 501
tyrosine kinase inhibitor therapy
bone marrow cellularity reduction 450
chronic myeloid leukaemia, BCR-ABL1 positive 423, 435
accelerated phase 433
chronic phase 433, 435
complete haematological remission 450
cytogenetic remission 450
FGFR1 rearrangements 501
mechanism of action 448, 450
molecular remission 450
morphological effects 435, 439, 444–450
ostemalacia risk 447
osteoposiosis risk 447
PDGFRα rearrangements 501
PDGFRβ rearrangements 501
second neoplasm risk 450
undifferentiated carcinoma, metastases 749, 750
uraemia, echinocytes 119, 120
uterine cervix carcinoma, metastases 749
vacuoles 25
see also individual cell types
varicella 562
VDF genes rearrangement, lymphoid neoplasms 588
vesiculated cells 116
morphology 115, 116, 116
viral infections
bone marrow changes 733
haemophagocytic syndrome 733
virgin (naïve) B cells 588
visceral leishmaniasis 721, 739
vitamin B12 deficiency
iron deficiency and 155
macrocytosis 104
mean cell volume 95–96

Waldenström macroglobulinaemia 590, 635–640, 681
blood count 638
bone marrow morphology 16, 639, 640, 641, 642
definition 635, 638
protein precipitates 640
red cell indices, paradoxical alterations 140, 173
spherocytes 114, 115
Weiss-Tsou-Seligman reaction, multiple myeloma 690
white blood cell count (WBC)
acute lymphoblastic leukaemia 554
AML 285
atypical chronic myeloid leukaemia 535, 550
chronic myeloid leukaemia, BCR-ABL1 positive 423
chronic myelomonocytic leukaemia 513
circulating erythroid blast counts 138, 172
haired cell leukaemia 615
juvenile myelomonocytic leukaemia 537
leukaemoid reaction 727
MDS 185
multiple myeloma 684
optimal area for 7
polycythaemia vera 455
prolymphocytic leukaemia 610
T-cell prolymphocytic leukaemia 649
white blood cells see leucocytes
white pulp nodules, splenic marginal zone lymphoma 622
Wilms tumour 744

World Health Organization (WHO)
acute lymphoblastic leukaemia classification 574
ambiguous lineage acute leukaemias classification 579
AML classification 288, 288–289
anaemia definition 92
B-cell non Hodgkin lymphoma classification 618
chronic eosinophilic leukaemia, not otherwise specified diagnostic criteria 500
chronic myelomonocytic leukaemia diagnostic criteria 512, 512
juvenile myelomonocytic leukaemia diagnostic criteria 540
lymphoid neoplasms classification 588, 589
MDS classification 182–183, 184
2008 248–268
blast cell subclassification 214, 237
dysplasia definition 249–250
morphological criteria 184
subtypes 248–249, 251
myelodysplastic/myeloproliferative neoplasms classification 511
myeloid neoplasms, new categories 391, 396–397
myeloproliferative neoplasms classification, 2008 422, 423
non-granular blast cell criteria 234
plasma cell neoplasms diagnostic criteria 683
World Health Organization-based Prognostic Score System (WPSS), MDS 183
Wright stain 7
zeiosis 192, 196
zidovudine 271